Clinical Trial Search

Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts

Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 49.6; 46.1 ml per square meter — p=0.61

Primary: To Compare 1-year Angiographic Patency of Radial Artery Grafts Versus Saphenous Vein Grafts in Patients Undergoing Elective Coronary Artery Bypass Graft (CABG) Surgery…

Primary: Short-term End Point — 61; 77 participants

Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47

Primary: Generic Mental Health-Related Quality of Life — 50.0; 46.2; 57.2 units on a scale

Primary: Quercetin-associated Change in Surgery-associated Inflammation — 9; 3; 87; 109 mg/L

Primary: MACCE — 80; 51 Participants — p=0.35

Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12

Primary: The Patency of Saphenous Vein Grafts — 76.5; 88.7; 82.8 percentage of patent SV grafts

Primary: Number of Patients With Post-operative Combined Endpoint (i.e. With One or More of the Following) — 13; 26 participants

Primary: Vein Graft Intimal Area — 4.1; 4.5 mm

Primary: Cognitive Function — 0.07; 0.12 Continuous cognitive change score

Primary: Left Ventricular Stroke Work Index (LVSWI) — 42; 43; 29; 28 g*m/m2

Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion

Primary: 1 Year Graft Patency Rates — 97.1; 97.1 percentage of distal anastomoses

Primary: Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year — 14; 16 Vein grafts

Primary: Number of Subjects With Adverse Events — 7; 4 Participants

Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L

Primary: Saphenous Vein Graft Occlusion — 17.4; 13.2 percentage of veins occluded

Primary: Reliability of Bidirectional Palpation Test (BPT) in Evaluating LIMA-LAD Graft Patency — 2; 2; 2; 2 Participants — p=<0.001

Primary: Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging — 14; 14 Participants — p=0.78

Primary: Procedural Success — 91.4 percentage of participants

Primary: Patency Rates — 38; 58; 6; 1 Participants

Primary: Post-op CK-MB Levels — 71.70; 92.66 IU/L — p=<0.05

Primary: Assessment of the Initial Risk of Surgery (EuroScore II). — 1.3; 1.07; 1.02 percent — p=0.24

Primary: Major Adverse Coronary and Cerebrovascular Events (MACCE) — 0.130; 0.111 MACCE Event Rate per Person-Year

Primary: Short Physical Performance Battery — 7.33; 8.00; 11.44; 10.90 units on a scale

Primary: Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death — 16; 17 Participants

Primary: Incidence of Adverse Events — 3; 3; 5; 4 participants